Our Team

Hans Peter joined the Board of Shield Therapeutics plc in July 2018. Mr. Hasler was the Chief Executive Officer of Vicarius Pharma AG, a privately held European biopharma company until 2020.  His prior experiences include Elan Corporation, Dublin, where he was Chief Operating Officer, and Biogen Inc., Boston, where his positions included Chief Operating Officer, and EVP, Head of Global Neurology and International.  Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as Senior Vice President, Chief Marketing Officer and beforehand Managing Director of Wyeth Group Germany, Münster.

Hans Peter Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland (SIX), Chairman of the Board of Shield Therapeutics, London (AIM), and a Director of Minerva Neurosciences in Boston (Nasdaq) and Gain Therapeutics, Bethesda (Nasdaq). He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.

Hans Peter is a member of the Remuneration Committee and chair of the Nomination Committee.

Peter has over 25 years’ experience in international M&A deals, company turnarounds, licensing transactions and financing activities including IPOs with particular experience in chemical and healthcare industries. He is currently CEO/CFO of Apeiron Biologics AG. Peter was CFO/CBO of Medigene AG between 2012 and 2016 and was fundamental in the turnaround process by out licensing marketed and legacy products and enhancing shareholder value with a new large international investor base. Prior to that he was CFO of Wilex AG, having orchestrated its IPO in 2006. Peter read Business Management, Banking, Marketing and Controlling in London, St. Gallen and Munich, and has a certificate in Business Studies from the University of London.

Peter is the chair of the Audit Committee and a member of the Nomination Committee.

Christian is one of the founders of Shield Therapeutics where he was responsible for the discovery and initial clinical development programs until 2012. He is an entrepreneurial senior medical affair, and clinical development executive with vast experience in both large and small pharmaceutical companies. He serves in various boards and will focus on Shield Therapeutics' medical, and scientific strategy. He is Managing Director of his own boutique consultancy business TACHRIS AG in Switzerland providing clinical, medical, medical marketing and strategic management consultancy services including pharmaceutical asset evaluation.

Dr Schweiger is also Lecturing Professor in Pharmaceutical Medicine at the University of Essen and actively working with different international patient and professional associations.

Christian is a member of the Remuneration and Nomination Committees.

Fabiana is currently Senior Vice President, Chief Compliance Officer at Aimmune Therapeutics based in San Francisco, California (a Nestlé Health Science Corporation since October 2020). She brings to Shield extensive experience in compliance having started and implemented compliance programs at several major pharmaceutical companies including Merck, Sharp & Dohme, Bristol-Myers Squibb Company, Mylan Laboratories and Elan Pharmaceuticals. Fabiana was also a Non-Executive Director at ArthroCare Corporation, a publicly traded company in the medical device sector prior to its acquisition by Smith & Nephew in 2014. Fabiana holds a Master's in Law from the University of California, a Doctor in Law and a Bachelor in Law from the Universidad de Buenos Aires and is the recipient of several international recognitions and has been published extensively in areas of leadership and compliance.

Fabiana is a member of the Audit and Nomination Committees.

Anders brings over 30 years of US & Global pharmaceutical/biotech experience. He served as the EVP, Chief Commercial Officer at Banner Life Sciences. His prior experience includes senior commercial and general management roles in AstraZeneca, Biogen, Orexo AB (where he was President and CEO), EMD Serono, and Santhera Pharmaceuticals. Anders holds an MSc in Pharmacy from Uppsala University and a Diploma in Business Administration from IHM, Stockholm.

Currently, he is the principal of his own consulting business, Lexington Biopharma Consulting, a Private Equity Adviser, and Co-founder of ReMyeTx, a neurology start-up company. 

Additionally, Anders serves as the Chair of the Remuneration Committee and is a member of the Nomination Committee.

Dr. Rudolf Widmann joined the board of Shield Therapeutics in 2024, bringing over 30 years of experience in the pharmaceutical industry and a deep commitment to advancing treatments for rare diseases. His passion for this field began during his pharmacy studies at the University of Innsbruck, where he focused on epilepsy and central nervous system disorders. He went on to work at the Max Planck Institute for Neurological Research, studying cerebral infarction, before transitioning to the private sector in 1991 with a role in quality management at IMMUNO.

In 1993, Dr. Widmann joined Wellcome Austria Pharma as Head of Medical Services, later moving to Glaxo-Wellcome as Senior Medical Marketing Adviser in the Hospital Business Unit after Glaxo’s acquisition of Wellcome. Witnessing a gap in the market for rare disease treatments, he founded AOP Health in 1996. As Chief Therapeutics Development Officer and later a Board Member of AOP Health International Management AG, he has been instrumental in leading the company's mission to provide essential therapies for underserved patient populations.